Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Candida is the most common fungal pathogen identified in hospitalized patients. This study
will seek to enroll adult patients (18 years of age or older) with invasive Candida
infections (involving deep tissues and organs). The study will not enroll patients whose only
site of Candida infection was the bloodstream. Patients that fulfill all study entry criteria
will receive a single daily dose of caspofungin. Caspofungin, an intravenous echinocandin
antifungal agent, is already approved for the treatment of invasive candidiasis. The dosage
strength and duration of caspofungin will be individualized for each patient based on
disease, severity of disease and extent of infection.